During today's CDC Advisory Committee on Immunization Practices (ACIP) meeting, committee members voted to recommend the FDA-authorized 2024-2025 COVID-19 vaccines for individuals aged 6 months and older. Additionally, they reaffirmed the existing influenza vaccination guidelines for the 2024-2025 season.
The test was validated as part of the NIH’s RADx tech program through its Independent Test Assessment Program, in collaboration with the FDA.
A Florida hospital takes a novel approach for the healthcare-associated infection and reduced inappropriate testing by setting up guidelines.
The federal agency says everyone 75 years of age and older should receive the RSV vaccine.
Jared Baeten, MD, PhD emphasizes the importance of the innovative PURPOSE 1 study in the fight against HIV, coinciding with National HIV Testing Day, today serves as a reminder of the ongoing efforts to expand testing access and develop new tools to combat HIV globally.
A retracted paper that erroneously claimed the measles, mumps and rubella (MMR) vaccine caused autism has repercussions still being felt today around topics such as vaccination, misinformation and disinformation, and measles incidence rates.
A case study of an 80-year-old patient, illustrating successful management of dual H pylori and C diff infections with quadruple therapy, with key insights from Yazan Abboud, MD and Sima Vossough-Teehan, MD.
The WHO reports the variant, clade I MPXV, has been circulating in a region within the Democratic Republic of Congo since last year.
Updates from June 24, 2024, on FDA-issued food recalls highlight potential issues such as Listeria contamination, mold growth, and undeclared allergens.
Findings from a pair of phase 2a trials showed combination imdusiran and IFN or VTP-300 with standard-of-care NA therapy led to meaningful and sustained reductions in HBsAg levels.
The study analyzed over 15 years shows declining rates of chronic and acute Hepatitis B in China, which is expected to make a significant contribution to the global elimination of hepatitis B by 2030.
Those individuals who received older versions of vaccines did not see significantly reduced risks of severe COVID-19 outcomes.
Researchers assess the efficacy of fecal microbiota transplantation (FMT) for first or second episodes of Cdifficile infection (CDI), demonstrating high initial cure rates and sustained in managing the condition.
In a small study, recurrent Clostridioides difficile infection (CDI) therapy, Rebyota, was durable in a majority of patients who were exposed to non-CDI antibiotics.
Jason Roberts, PhD, notes that the BLING study has been a great success for infectious diseases and critical care as a research program, providing strong evidence supporting a meaningful intervention for patients, specifically in clinical cure rates and the occurrence of infections with multiresistant organisms.
Research presented at ASHP 2024 found that concerns around the safety of COVID-19 vaccines and the credibility of information from public health authorities were the biggest drivers of vaccine hesitancy during the COVID-19 pandemic.
Jason Roberts, PhD, discusses insights from the BLING III trial, outlining its study design and primary outcomes. His analysis centers on the clinical benefits of continuous infusions while addressing the complexities of antibiotic administration in critical care. This is part 1 of a 2-part series.
Social determinants of health may determine hepatitis C management in the outpatient setting.
Michigan is taking decisive action to support dairy farms affected by the recent outbreak of highly pathogenic avian influenza (HPAI).
FDA approves pneumococcal vaccine V116, Salmonella outbreak linked to a household pet, Japan is currently facing an unprecedented surge in cases of streptococcal toxic shock syndrome, and more this week from Contagion.
Berkeley Heights, NJ-based biopharmaceutical company, CorMedix, is working towards an expanded indication for its DefenCath product, for the prevention of these healthcare-associated infections.
Snapchill coffee products recalled over botulinum toxin concerns.
Understanding the evolving trends in antibiotic resistance among S aureus infections, commonly treated empirically with oral non–β-lactam antibiotics, is essential for guiding effective treatment strategies.
In the last segment of the series, Jones offered his insights for when he considers discharging patients.
In this conversation, Jones discussed concerns around empirical antimicrobial treatment and opportunities to narrow down therapies.
Zero HIV infections from the Phase 3 PURPOSE 1 Trial underscore the importance of innovative HIV prevention strategies across diverse populations.
Findings from the TAC ANRS 12311 trial revealed the success of tailored treatment combinations to the specific genotype of HCV to optimize efficacy and minimize adverse effects.
HCV testing was accepted by more than 80% of patients undergoing mammography and resulted in prompt linkage to care.
With the recent phase 3 data results of the Moderna COVID-19-influenza combination vaccine, the company is working towards regulatory approval and opens the door to possible protection against multiple viruses with less immunizations.
In a 17-year study across 2 Québec hospitals, researchers explored the relationship between antibiotic use and healthcare-associated Clostridioides difficile infections.
